Loading company
Cullinan Therapeutics, Inc.
CGEM · Nasdaq · ·
Next earnings: November 5, 2026
$15.24+1.9%Sep 29 close
- 1M
- -29.8%
- 6M
- +13.6%
- 1Y
- +157.0%
- 5Y
- -36.2%
CGEM · Nasdaq · ·
Next earnings: November 5, 2026
$15.24+1.9%Sep 29 close
Cullinan Therapeutics, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2022, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2022 | 3 months toDec 31, 2021 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$53.7M | -$70.1M | +23.34% |
| Profit per share | -$0.69 | -$0.91 | +24.18% |
| Free Cash Flow | -$38.1M | -$38.2M | +0.33% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“At our recent Immunology Day event, we shared compelling initial clinical data for CLN-978 and velinotamig, two T cell engagers with potential to achieve immune reset and transform outcomes for people living with autoimmune diseases. We look forward to sharing additional clinical data throughout the remainder of 2026 as we rapidly advance these programs towards Phase 2 studies,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/ , and follow Cullinan on LinkedIn and X .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Cullinan Therapeutics, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Cullinan Therapeutics, Inc. has no earnings call transcript available.